-
FDA Approves Pimjetmi (pimicotinib) for Tenosynovial Giant Cell Tumor (TGCT)
A New Treatment Option for Patients The U.S. Food and Drug Administration (FDA) has officially approved Pimjetmi (pimicotinib), a significant advancement for adult patients living with tenosynovial giant cell tumor (TGCT). This condition is a rare, non-malignant tumor that affects the synovium, bursae, and tendon sheaths, often causing severe pain, joint swelling, and significant functional…
-
FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention
WHIPPANY, N.J.– November 9, 2026 — Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with… Source: Read More
-
A Breakthrough in Lung Cancer Treatment: FDA Approves Rybrevant + Lazertinib Combination
NYSE: $JNJ A New Frontier in Targeted Therapy In a significant development for oncology, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib. This treatment is specifically indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung…
-
FDA Approves Lucamzi: A New Biosimilar Option for Retinal Conditions
A New Milestone in Ophthalmology The landscape for treating serious eye conditions has expanded. The U.S. Food and Drug Administration (FDA) has officially approved Lucamzi (ranibizumab-blrz), a biosimilar to the well-known reference product, Lucentis. This approval marks an important step in providing healthcare providers and patients with additional treatment alternatives for managing vision-related diseases. What…
-
New Treatment Option Approved: Ilumya (tildrakizumab-asmn) for Psoriatic Arthritis
A New Milestone for Psoriatic Arthritis Care The U.S. Food and Drug Administration (FDA) has officially approved Ilumya (tildrakizumab-asmn) for the treatment of adults living with active psoriatic arthritis (PsA). This approval provides a significant new therapeutic option for patients managing this complex, inflammatory condition. Understanding Ilumya Ilumya is a humanized interleukin-23 (IL-23) p19 subunit…
-
A Breakthrough in Rare Disease: FDA Grants Accelerated Approval to Voceryq
NASDAQ: $INO New Hope for Patients with Dystrophic Epidermolysis Bullosa The medical community is celebrating a significant milestone in genetic medicine. The U.S. Food and Drug Administration (FDA) has officially granted accelerated approval to Voceryq (beremagene geperpavec-svdt), a transformative gene therapy designed to treat wounds in patients aged 6 months and older with dystrophic epidermolysis…
-
A Breakthrough for IgA Nephropathy: Ultomiris Receives FDA Accelerated Approval
A New Option for Kidney Health The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab-cwvz) for the treatment of adults with immunoglobulin A nephropathy (IgAN). This milestone marks Ultomiris as the first and only C5 complement inhibitor indicated to reduce proteinuria in patients with this progressive kidney disease. Understanding the…
-
New Treatment Option for HAE: BioCryst Receives FDA Approval for Orladeyo Oral Pellets
NASDAQ: $BCRX A Milestone for HAE Patients BioCryst Pharmaceuticals has reached a significant milestone in the management of Hereditary Angioedema (HAE). The U.S. Food and Drug Administration (FDA) has officially approved Orladeyo (berotralstat) 150 mg oral pellets. This approval provides a new, convenient treatment option for adults and adolescents aged 12 years and older looking…
-
New Treatment Milestone: FDA Approves Subcutaneous Induction Regimen for Skyrizi
NYSE: $ABBV A New Step Forward for Ulcerative Colitis Treatment The landscape of treatment for adults living with moderately to severely active ulcerative colitis (UC) has officially expanded. The FDA has approved a new subcutaneous induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa), providing patients with a new, flexible option for managing their condition. What This Approval…
-
A New Era for Diabetes Care: FDA Approves Awiqli for Children and Adolescents
NYSE: $NVO A Breakthrough in Insulin Therapy Managing type 1 and type 2 diabetes has long required the demanding routine of daily insulin injections. However, a significant advancement has arrived. The FDA has officially approved Awiqli (insulin icodec), marking it as the first and only once-weekly basal insulin for children and adolescents aged 10 years…
-
Viatris Receives U.S. FDA Approval for Ryzumvi for the Treatment of Presbyopia
NASDAQ: $VTRS PITTSBURGH, Oct. 16, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of… Source: Read More
-
Clearer Eyes Ahead: FDA Approves Upneeq (Apraclonidine) for Eye Redness
NYSE: $ALC A New Solution for Eye Redness Dealing with persistent eye redness can be frustrating, often affecting both comfort and appearance. Recently, the FDA provided a new option for patients by approving Upneeq (apraclonidine hydrochloride ophthalmic solution), a prescription eye drop designed to address this common concern. What You Should Know About Upneeq Upneeq…
-
New Treatment Option: Cosette Pharmaceuticals Receives FDA Approval for Evoxac Oral Solution
A New Milestone in Dry Mouth Treatment Patients suffering from the symptoms of Sjogren’s syndrome now have a new way to manage their condition. Cosette Pharmaceuticals, Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted approval for Evoxac (cevimeline HCl) oral solution (15 mg/5 mL). This approval marks an important…
-
New Hope for Chronic Hepatitis B: Understanding the FDA Approval of Hepcludex (bepirovirsen)
NYSE: $GSK A Significant Milestone in Liver Health The landscape of chronic hepatitis B (CHB) treatment is evolving. Recently, the FDA reached a significant decision regarding Hepcludex (bepirovirsen), providing new options for patients managing this complex viral infection. This development marks a noteworthy step forward in therapeutic approaches for those living with chronic liver disease.…
-
UCB Announces U.S. FDA Approval for Zilbrysq (zilucoplan) Autoinjector Self-administration for Adults Living with Generalized Myasthenia Gravis
Brussels, Belgium and Atlanta, Georgia – October 16, 2026 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered… Source: Read More
-
Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
NYSE: $GSK Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite… Source: Read More
-
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
South San Francisco, CA — October 15, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of… Source: Read More
-
FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder
September 29, 2026 — Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Lamlique&trade… Source: Read More
-
New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment
NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…
-
FDA Approves Tecentriq Combination as Adjuvant Therapy for Specific Colon Cancer
A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…
-
FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia
PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has… Source: Read More
-
A New Frontier in Treatment: FDA Approves Hovilpri (pritelivir) for Resistant HSV
A Breakthrough for Immunocompromised Patients For individuals living with immunocompromised conditions, managing mucocutaneous herpes simplex virus (HSV) can be a persistent and painful challenge. Recently, the medical community reached a significant milestone as the FDA approved Hovilpri (pritelivir), offering a new therapeutic option for those who struggle with lesions that do not respond to conventional…
-
FDA Approves Updated Nuvaxovid Vaccine for the 2026-2027 Season
NASDAQ: $NVAX Staying Ahead of COVID-19: The Latest Vaccine Update The landscape of COVID-19 vaccination continues to evolve to provide the most effective protection against circulating variants. Recently, the U.S. Food and Drug Administration (FDA) took a significant step by approving the XBB.1.5-adapted Nuvaxovid vaccine for the upcoming 2026-2027 vaccination season. What You Need to…
-
A Breakthrough for Alexander Disease: FDA Approves Zilganersen (Zanvastro)
NASDAQ: $IONS A New Horizon for Patients The FDA has officially granted approval for Zanvastro (zilganersen), a significant milestone for individuals living with Alexander disease (AxD). This rare, progressive, and fatal neurological disorder has long lacked targeted treatment options, making this approval a vital step forward for the medical community and patient families. Understanding Alexander…